Genomic Health and Pfizer plan to develop a genomic test based on the diagnostic company’s Oncotype DX technology to gauge the risk of post-operative kidney cancer recurrence.
 
The project, announced this week, is designed to create a test for patients with Stage I-III, localized, clear cell-type renal carcinoma.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A company hopes to capture the genetic diversity in India to power tailored therapeutics, BBC News reports.

Researchers tie variants in seven genes to insomnia risk, Live Science reports.

The US Environmental Protection Agency has approved an RNAi-based insecticide, according to the Atlantic.

In PLOS this week: locus near OAS1 linked to Sjogren's syndrome, rotavirus reassortment events uncovered by sequencing, and more.